Importantly, 1,25(OH)2D3-treated DC from both healthy controls and MS patients displayed a significantly lower expression of CD86, CD83, and HLA-DR upon stimulation with a proinflammatory cytokine cocktail in comparison with conventional DC. The gene discussed is CD83; the disease is myeloid sarcoma.